Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

Полное описание

Библиографические подробности

Главные авторы:	Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2023-11-01
Серии:	Frontiers in Oncology
Предметы:	clinical outcome toxicity low-and intermediate-risk radiotherapy prostate cancer stereotactic body radiation
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!